Antimicrobial agents and chemotherapy

publication venue for

Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis. 2016
PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. 2014
Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis. 2025
Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study.. 69. 2025
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of Enterobacterales from outpatient centers and nursing homes across the United States (2022-2024).. 69. 2025
In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections.. 68. 2024
Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.. 67. 2023
Case Commentary: Unlocking the Potential of Bacteriophage to Prevent Recurrent Urinary Tract Infections after Kidney Transplantation.. 67. 2023
Functional Diversity of Gram-Negative Permeability Barriers Reflected in Antibacterial Activities and Intracellular Accumulation of Antibiotics.. 67. 2023
Efficacy of Cefiderocol in Experimental Stenotrophomonas maltophilia Pneumonia in Persistently Neutropenic Rabbits.. 66. 2022
Candida auris Pan-Drug-Resistant to Four Classes of Antifungal Agents.. 66. 2022
Elevated MICs of Susceptible Antipseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant Pseudomonas aeruginosa: Implications for Dose Optimization.. 65. 2021
Analysis of Multidrug Resistance in Staphylococcus aureus with a Machine Learning-Generated Antibiogram.. 65. 2021
Structure-Activity Relationship Analysis of Benzotriazine Analogues as HIV-1 Latency-Reversing Agents.. 64. 2020
Activity of Epigenetic Inhibitors against Plasmodium falciparum Asexual and Sexual Blood Stages.. 64. 2020
A Histone Methyltransferase Inhibitor Can Reverse Epigenetically Acquired Drug Resistance in the Malaria Parasite Plasmodium falciparum.. 64. 2020
Tissue Distribution of Doxycycline in Animal Models of Tuberculosis.. 64. 2020
Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.. 64. 2020
Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV.. 64. 2020
Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia.. 63. 2019
Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae.. 63. 2019
Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance.. 63. 2019
Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens.. 63. 2019
U.S.-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016.. 63. 2019
Molecular Analysis of Resistance and Detection of Non-Wild-Type Strains Using Etest Epidemiological Cutoff Values for Amphotericin B and Echinocandins for Bloodstream Candida Infections from a Tertiary Hospital in Qatar.. 62. 2018
Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.. 62. 2018
Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.. 62. 2018
Chemical Genetic Interaction Profiling Reveals Determinants of Intrinsic Antibiotic Resistance in Mycobacterium tuberculosis.. 61. 2017
Combination Therapy with Isavuconazole and Micafungin for Treatment of Experimental Invasive Pulmonary Aspergillosis.. 61. 2017
Multicenter Clinical and Molecular Epidemiological Analysis of Bacteremia Due to Carbapenem-Resistant Enterobacteriaceae (CRE) in the CRE Epicenter of the United States.. 61. 2017
New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae.. 61. 2017
Evaluation of a Multiplex PCR Assay To Rapidly Detect Enterobacteriaceae with a Broad Range of β-Lactamases Directly from Perianal Swabs.. 60. 2016
Monitoring Antimicrobial Resistance in the Food Supply Chain and Its Implications for FDA Policy Initiatives.. 60. 2016
Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.. 60. 2016
Barrier-Independent, Fitness-Associated Differences in Sofosbuvir Efficacy against Hepatitis C Virus.. 60. 2016
Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections.. 60. 2016
Klebsiella pneumoniae Isolate from a New York City Hospital Belonging to Sequence Type 258 and Carrying blaKPC-2 and blaVIM-4.. 60. 2016
Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model.. 60. 2015
Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods.. 59. 2015
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.. 59. 2015
U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.. 59. 2015
Fast hepatitis C virus RNA elimination and NS5A redistribution by NS5A inhibitors studied by a multiplex assay approach.. 59. 2015
Kidney injury associated with telavancin dosing regimen in an animal model.. 59. 2015
Identification and characterization of linezolid-resistant cfr-positive Staphylococcus aureus USA300 isolates from a New York City medical center.. 58. 2014
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.. 58. 2014
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.. 58. 2014
Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents.. 58. 2014
Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.. 58. 2014
Pharmacodynamic target attainment for various ceftazidime dosing schemes in high-flux hemodialysis.. 57. 2013
Pharmacokinetic and in vivo efficacy studies of the mycobactin biosynthesis inhibitor salicyl-AMS in mice.. 57. 2013
Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis.. 57. 2013
Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.. 56. 2012
Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design.. 56. 2012
Multiplex real-time PCR for detection of an epidemic KPC-producing Klebsiella pneumoniae ST258 clone.. 56. 2012
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques.. 56. 2012
Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.. 56. 2012
Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.. 56. 2012
Simulated antibiotic exposures in an in vitro hollow-fiber infection model influence toxin gene expression and production in community-associated methicillin-resistant Staphylococcus aureus strain MW2.. 56. 2011
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.. 55. 2011
Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.. 55. 2011
Effect of antifungal therapy timing on mortality in cancer patients with candidemia.. 54. 2009
Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.. 53. 2009
Virologic response to lopinavir-ritonavir-based antiretroviral regimens in a multicenter international clinical cohort: comparison of genotypic interpretation scores.. 52. 2008
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States.. 52. 2008
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004.. 51. 2007
Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.. 49. 2005
Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread.. 48. 2004
Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.. 48. 2004
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.. 47. 2003
Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.. 47. 2003
In vitro activities of newer quinolones against bacteroides group organisms.. 46. 2002
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.. 46. 2002
Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.. 45. 2001
Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.. 45. 2001
Antimicrobial susceptibility of Ehrlichia phagocytophila.. 45. 2001
Suppression of posttreatment recurrence of experimental visceral Leishmaniasis in T-cell-deficient mice by oral miltefosine.. 44. 2000
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group.. 44. 2000
Activities of poloxamer CRL-1072 against Mycobacterium avium in macrophage culture and in mice.. 43. 1999
Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.. 43. 1999
Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection.. 43. 1999
Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.. 40. 1996
Penetration of ceftibuten into middle ear fluid.. 40. 1996
Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.. 40. 1996
Activities of poloxamer CRL8131 against Mycobacterium tuberculosis in vitro and in vivo.. 39. 1995
Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci.. 39. 1995
Comparative in vitro activities of L-695,256, a novel carbapenem, against gram-positive bacteria.. 39. 1995
Treatment of exogenous Candida endophthalmitis in rabbits with oral fluconazole.. 39. 1995
Enhancement of antibiotic susceptibility and suppression of Mycobacterium avium complex growth by poloxamer 331.. 39. 1995
Low-dose dexamethasone as adjunctive therapy for disseminated Mycobacterium avium complex infections in AIDS patients.. 38. 1994
Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.. 38. 1994
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.. 38. 1994
Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine.. 37. 1993
In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.. 37. 1993
In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.. 37. 1993
Discrimination of extended-spectrum beta-lactamases by a novel nitrocefin competition assay.. 34. 1990
Novel plasmid-mediated beta-lactamase (MIR-1) conferring resistance to oxyimino- and alpha-methoxy beta-lactams in clinical isolates of Klebsiella pneumoniae.. 34. 1990
Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility.. 34. 1990
Differences in susceptibilities of species of the Bacteroides fragilis group to several beta-lactam antibiotics: indole production as an indicator of resistance.. 22. 1982
Minimal nephrotoxicity with cephalosporin-aminoglycoside combinations in patients with neoplastic disease.. 21. 1982
Nafcillin therapy for Staphylococcus aureus endocarditis.. 14. 1978
Treatment of chronic typhoid carriers with ampicillin.. 3. 1973
Questionable susceptibility reporting in a multicenter trial. 1995
Effect of novobiocin-containing antimicrobial regimens on infection and colonization with vancomycin-resistant Enterococcus faecium. 1995
Treatment of severe pneumonia with ciprofloxacin or imipenem. 1994
Clinical and experimental advances in treatment of visceral leishmaniasis. 2001

VIVO Weill Cornell Medical College

Antimicrobial agents and chemotherapy Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)